Literature DB >> 21837081

6-Bromo-3-methyl-2-phenyl-3H-imidazo[4,5-b]pyridine.

Younes Ouzidan, El Mokhtar Essassi, Santiago V Luis, Michael Bolte, Lahcen El Ammari.   

Abstract

The two fused five- and six-membered rings building the mol-ecule of the title compound, C(13)H(10)BrN(3), are approximately planar, the largest deviation from the mean plane being 0.004 (2) Å. The dihedral angle between the imidazo[4,5-b]pyridine mean plane and that of the phenyl ring is 41.84 (11)°. The structure is held together by slipped π-π stacking between symmetry-related mol-ecules, with an inter-planar distance of 3.583 (1) Å and a centroid-centroid vector of 3.670 (2) Å.

Entities:  

Year:  2011        PMID: 21837081      PMCID: PMC3151993          DOI: 10.1107/S1600536811022318

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For background regarding biological activity of imidazo[4,5-b]pyridines, see: Cristalli et al. (1995 ▶); Bukowski & Kaliszan (1991 ▶); Aridoss et al. (2006 ▶); Bavetsias et al. (2007 ▶). For background to their pharmacological activity, see: Chen & Dost (1992 ▶); Weier et al. (1993 ▶).

Experimental

Crystal data

C13H10BrN3 M = 288.15 Orthorhombic, a = 13.7138 (4) Å b = 6.7088 (2) Å c = 25.3217 (7) Å V = 2329.68 (12) Å3 Z = 8 Mo Kα radiation μ = 3.51 mm−1 T = 298 K 0.60 × 0.30 × 0.06 mm

Data collection

Bruker SMART CCD three-circle diffractometer Absorption correction: multi-scan (SADABS; Bruker, 1997 ▶) T min = 0.227, T max = 0.825 13535 measured reflections 2378 independent reflections 1804 reflections with I > 2σ(I) R int = 0.047

Refinement

R[F 2 > 2σ(F 2)] = 0.033 wR(F 2) = 0.090 S = 1.04 2378 reflections 155 parameters H-atom parameters constrained Δρmax = 0.37 e Å−3 Δρmin = −0.40 e Å−3 Data collection: SMART (Bruker, 1997 ▶); cell refinement: SAINT (Bruker, 1997 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEPIII (Burnett & Johnson, 1996 ▶) and ORTEP-3 for Windows (Farrugia, 1997 ▶); software used to prepare material for publication: WinGX (Farrugia, 1999 ▶). Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S1600536811022318/dn2697sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536811022318/dn2697Isup2.hkl Supplementary material file. DOI: 10.1107/S1600536811022318/dn2697Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C13H10BrN3F(000) = 1152
Mr = 288.15Dx = 1.643 Mg m3
Orthorhombic, PbcaMo Kα radiation, λ = 0.71073 Å
Hall symbol: -P 2ac 2abCell parameters from 5157 reflections
a = 13.7138 (4) Åθ = 3.0–29.6°
b = 6.7088 (2) ŵ = 3.51 mm1
c = 25.3217 (7) ÅT = 298 K
V = 2329.68 (12) Å3Platelet, colourless
Z = 80.60 × 0.30 × 0.06 mm
Bruker CCD three-circle diffractometer2378 independent reflections
Radiation source: fine-focus sealed tube1804 reflections with I > 2σ(I)
graphiteRint = 0.047
ω scansθmax = 26.4°, θmin = 2.2°
Absorption correction: multi-scan (SADABS; Bruker, 1997)h = 0→17
Tmin = 0.227, Tmax = 0.825k = 0→8
13535 measured reflectionsl = 0→31
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.033Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.090H-atom parameters constrained
S = 1.04w = 1/[σ2(Fo2) + (0.0361P)2 + 1.2509P] where P = (Fo2 + 2Fc2)/3
2378 reflections(Δ/σ)max = 0.002
155 parametersΔρmax = 0.37 e Å3
0 restraintsΔρmin = −0.40 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against all reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on all data will be even larger.
xyzUiso*/Ueq
Br10.65259 (2)1.16657 (6)0.626463 (10)0.06788 (15)
N10.60483 (17)0.7251 (3)0.51723 (8)0.0509 (6)
N20.60942 (14)0.7570 (3)0.42245 (7)0.0396 (4)
N30.64274 (15)1.0833 (3)0.41558 (8)0.0425 (5)
C10.6160 (2)0.8347 (4)0.56091 (10)0.0528 (7)
H10.60930.77190.59340.063*
C20.63682 (17)1.0361 (4)0.56042 (9)0.0477 (6)
C30.64811 (18)1.1434 (4)0.51422 (10)0.0464 (6)
H30.66201.27900.51380.056*
C40.63692 (16)1.0313 (4)0.46819 (9)0.0385 (5)
C50.61634 (17)0.8291 (3)0.47310 (9)0.0386 (5)
C60.62568 (16)0.9162 (4)0.38966 (9)0.0369 (5)
C70.62409 (16)0.9055 (4)0.33165 (9)0.0378 (5)
C80.58108 (18)1.0590 (4)0.30370 (9)0.0463 (6)
H80.55251.16440.32180.056*
C90.5801 (2)1.0574 (5)0.24902 (10)0.0561 (7)
H90.55061.16100.23060.067*
C100.6226 (2)0.9037 (5)0.22203 (11)0.0590 (8)
H100.62170.90250.18530.071*
C110.6665 (2)0.7515 (6)0.24919 (12)0.0641 (8)
H110.69570.64760.23070.077*
C120.66776 (19)0.7512 (5)0.30402 (11)0.0531 (7)
H120.69780.64750.32220.064*
C130.5829 (2)0.5528 (4)0.40922 (12)0.0607 (8)
H13A0.54610.55180.37700.091*
H13B0.54410.49730.43720.091*
H13C0.64090.47460.40480.091*
U11U22U33U12U13U23
Br10.0669 (2)0.0970 (3)0.03975 (18)−0.00449 (16)−0.00264 (12)−0.01196 (14)
N10.0583 (14)0.0484 (13)0.0460 (12)−0.0094 (11)−0.0071 (10)0.0159 (10)
N20.0467 (11)0.0275 (10)0.0445 (11)−0.0009 (9)−0.0056 (9)0.0035 (9)
N30.0584 (13)0.0312 (10)0.0379 (10)−0.0030 (9)0.0000 (9)0.0023 (9)
C10.0529 (15)0.0641 (19)0.0414 (14)−0.0091 (14)−0.0064 (11)0.0176 (13)
C20.0411 (13)0.0662 (19)0.0358 (12)−0.0012 (12)−0.0042 (10)0.0006 (12)
C30.0526 (15)0.0436 (15)0.0430 (13)−0.0035 (11)−0.0023 (11)−0.0017 (11)
C40.0427 (13)0.0344 (13)0.0385 (12)−0.0008 (10)−0.0019 (9)0.0043 (10)
C50.0385 (12)0.0347 (12)0.0426 (12)−0.0022 (10)−0.0061 (10)0.0066 (10)
C60.0381 (12)0.0316 (12)0.0410 (12)0.0030 (10)−0.0028 (10)0.0016 (10)
C70.0362 (11)0.0391 (13)0.0380 (12)−0.0019 (10)0.0003 (9)−0.0014 (10)
C80.0522 (14)0.0459 (15)0.0408 (13)0.0073 (12)0.0051 (11)0.0026 (11)
C90.0575 (16)0.071 (2)0.0402 (14)0.0032 (14)0.0022 (12)0.0109 (13)
C100.0541 (15)0.084 (2)0.0389 (14)−0.0069 (16)0.0070 (12)−0.0068 (14)
C110.0615 (19)0.071 (2)0.0594 (18)0.0084 (16)0.0145 (14)−0.0249 (17)
C120.0514 (16)0.0528 (16)0.0551 (16)0.0114 (13)0.0018 (12)−0.0064 (14)
C130.087 (2)0.0329 (14)0.0622 (17)−0.0136 (14)−0.0098 (15)−0.0003 (13)
Br1—C21.900 (3)C7—C81.382 (3)
N1—C51.327 (3)C7—C121.386 (4)
N1—C11.337 (3)C8—C91.385 (3)
N2—C61.371 (3)C8—H80.9300
N2—C51.374 (3)C9—C101.367 (4)
N2—C131.456 (3)C9—H90.9300
N3—C61.320 (3)C10—C111.371 (5)
N3—C41.380 (3)C10—H100.9300
C1—C21.381 (4)C11—C121.388 (4)
C1—H10.9300C11—H110.9300
C2—C31.382 (4)C12—H120.9300
C3—C41.395 (3)C13—H13A0.9600
C3—H30.9300C13—H13B0.9600
C4—C51.391 (3)C13—H13C0.9600
C6—C71.471 (3)
C5—N1—C1113.2 (2)C8—C7—C6118.8 (2)
C6—N2—C5106.23 (19)C12—C7—C6122.3 (2)
C6—N2—C13129.4 (2)C7—C8—C9120.7 (3)
C5—N2—C13124.3 (2)C7—C8—H8119.7
C6—N3—C4104.8 (2)C9—C8—H8119.7
N1—C1—C2123.7 (2)C10—C9—C8120.1 (3)
N1—C1—H1118.2C10—C9—H9119.9
C2—C1—H1118.2C8—C9—H9119.9
C1—C2—C3122.7 (2)C9—C10—C11119.9 (3)
C1—C2—Br1117.80 (19)C9—C10—H10120.1
C3—C2—Br1119.5 (2)C11—C10—H10120.1
C2—C3—C4114.5 (2)C10—C11—C12120.6 (3)
C2—C3—H3122.8C10—C11—H11119.7
C4—C3—H3122.8C12—C11—H11119.7
N3—C4—C5110.2 (2)C7—C12—C11119.9 (3)
N3—C4—C3131.6 (2)C7—C12—H12120.1
C5—C4—C3118.2 (2)C11—C12—H12120.1
N1—C5—N2126.4 (2)N2—C13—H13A109.5
N1—C5—C4127.7 (2)N2—C13—H13B109.5
N2—C5—C4105.9 (2)H13A—C13—H13B109.5
N3—C6—N2112.9 (2)N2—C13—H13C109.5
N3—C6—C7122.7 (2)H13A—C13—H13C109.5
N2—C6—C7124.3 (2)H13B—C13—H13C109.5
C8—C7—C12118.9 (2)
  5 in total

1.  Synthesis and in vitro microbiological evaluation of imidazo(4,5-b)pyridinylethoxypiperidones.

Authors:  G Aridoss; S Balasubramanian; P Parthiban; S Kabilan
Journal:  Eur J Med Chem       Date:  2005-12-27       Impact factor: 6.514

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Imidazo[4,5-b]pyridine derivatives of potential tuberculostatic activity. Part 1: Synthesis and quantitative structure-activity relationships.

Authors:  L Bukowski; R Kaliszan
Journal:  Arch Pharm (Weinheim)       Date:  1991-02       Impact factor: 3.751

4.  Synthesis and biological evaluation of N6-cycloalkyl derivatives of 1-deazaadenine nucleosides: a new class of anti-human immunodeficiency virus agents.

Authors:  G Cristalli; S Vittori; A Eleuteri; R Volpini; E Camaioni; G Lupidi; N Mahmood; F Bevilacqua; G Palù
Journal:  J Med Chem       Date:  1995-09-29       Impact factor: 7.446

5.  Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.

Authors:  Vassilios Bavetsias; Chongbo Sun; Nathalie Bouloc; Jóhannes Reynisson; Paul Workman; Spiros Linardopoulos; Edward McDonald
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

  5 in total
  2 in total

1.  N-tert-Butyl-2-(2,6-di-chloro-phen-yl)imidazo[1,2-a]pyrazin-3-amine.

Authors:  Zeenat Fatima; Thothadri Srinivasan; Suman Koorathota; Sathiah Thennarasu; Devadasan Velmurugan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-25

2.  N-tert-Butyl-2-[4-(dimethyl-amino)-phen-yl]imidazo[1,2-a]pyrazin-3-amine.

Authors:  Zeenat Fatima; Thothadri Srinivasan; Suman Koorathota; Sathiah Thennarasu; Devadasan Velmurugan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-03-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.